{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:32:51Z","timestamp":1787506371516,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To characterise the natural history of poor-responder neovascular age-related macular degeneration (AMD) by tracking structural evolution and visual decline over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective longitudinal study analysed 70 eyes of 70 treatment-naive neovascular AMD patients who completed loading dose therapy, received \u22657 injections in the first year, and experienced \u226510 ETDRS letter visual acuity (BCVA) loss from post-loading baseline. Spectral-domain OCT imaging and BCVA were evaluated at three timepoints: baseline (post-loading), 10-letter loss, and worst visual outcome. Multivariate regression analysis identified independent predictors of visual acuity at each timepoint. Primary structural parameters assessed included macular atrophy, subretinal fibrosis, external limiting membrane (ELM) and ellipsoid zone (EZ) integrity, central retinal thickness (CRT), and fluid parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean follow-up was 38.5\u2009\u00b1\u200922.8 months. Macular atrophy progression was dramatic (7.1%\u2009\u2192\u200941.4%\u2009\u2192\u200981.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and subretinal fibrosis increased substantially (11.4%\u2009\u2192\u200925.7%\u2009\u2192\u200957.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). CRT showed paradoxical biphasic evolution (262.6\u2009\u2192\u2009278.6\u2009\u2192\u2009252.0\u2009\u03bcm). Multivariate analysis revealed three distinct phases: no independent predictors at baseline, comprehensive multi-pathway model at 10-letter loss with subretinal fibrosis (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u2009\u22120.536), hyperreflective material (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u2009\u22120.350), and intraretinal fluid (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u2009\u22120.223) as independent predictors (R\u00b2\u2009=\u20090.428), and fibrotic dominance at worst outcome where subretinal fibrosis emerged as the sole predictor (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u2009\u22120.469, R\u00b2\u2009=\u20090.220). CRT showed no predictive value across all timepoints.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Poor-responder neovascular AMD follows a three-phase evolutionary journey with subretinal fibrosis as the dominant independent predictor of visual decline. These findings demand a paradigmatic shift toward qualitative structural assessment focusing on fibrotic changes rather than thickness-based monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04306-6","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:33:59Z","timestamp":1771320839000},"page":"827-834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The progressive journey of poor-responder neovascular AMD: tracking structural evolution and visual decline over time"],"prefix":"10.1038","volume":"40","author":[{"given":"Ilaria","family":"Lolli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Pignataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba Chiara","family":"Termite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ribezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8768-899X","authenticated-orcid":false,"given":"Giacomo","family":"Boscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-5031","authenticated-orcid":false,"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Reibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Boscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-967X","authenticated-orcid":false,"given":"Pasquale","family":"Viggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"4306_CR1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"4306_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"4306_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GA, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897\u2013908.","journal-title":"N Engl J Med"},{"key":"4306_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al.Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193\u2013201.","journal-title":"Ophthalmology"},{"key":"4306_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/IAE.0000000000001496","volume":"38","author":"D Barthelmes","year":"2018","unstructured":"Barthelmes D, Nguyen V, Daien V, Campain A, Walton R, Guymer R, et al. Two year outcomes of \u201ctreat and extend\u201d Intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina. 2018;38:20\u20138.","journal-title":"Retina"},{"key":"4306_CR6","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1136\/bjophthalmol-2014-305673","volume":"98","author":"C Chee Yee","year":"2014","unstructured":"Chee Yee C, Papakostas TD, Vavvas DG. Quantitative assessment of central retinal thickness in recurrent neovascular age-related macular degeneration. Br J Ophthalmol. 2014;98:1308.","journal-title":"Br J Ophthalmol"},{"key":"4306_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1136\/bjophthalmol-2013-304399","volume":"98","author":"L Reznicek","year":"2014","unstructured":"Reznicek L, Muhr J, Ulbig M, Kampik A, Mayer WJ, Haritoglou C, et al. Visual acuity and central retinal thickness: fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care. Br J Ophthalmol. 2014;98:1333\u20137.","journal-title":"Br J Ophthalmol"},{"key":"4306_CR8","doi-asserted-by":"crossref","unstructured":"Borrelli E, Foti C, Ulla L, Porreca A, Introini U, Grassi MO, et al. Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration. Br J Ophthalmol. 2025;109:875\u201381. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40122580\/","DOI":"10.1136\/bjo-2024-326152"},{"key":"4306_CR9","doi-asserted-by":"crossref","unstructured":"Borrelli E, Barresi C, Ricardi F, Berni A, Grosso D, Viggiano P, et al. Distinct pathways of macular atrophy in type 3 macular neovascularization associated with AMD. Investig Ophthalmol Vis Sci. 2024;65. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38470327\/","DOI":"10.1167\/iovs.65.3.18"},{"key":"4306_CR10","doi-asserted-by":"crossref","unstructured":"Ricardi F, Borrelli E, Boscia G, Gelormini F, Marica V, Conte F, et al. Relationship of Topographic distribution of macular atrophy secondary to neovascular AMD and reading performance. Investig Ophthalmol Vis Sci. 2024;65. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38289615\/","DOI":"10.1167\/iovs.65.1.44"},{"key":"4306_CR11","doi-asserted-by":"crossref","unstructured":"Viggiano P, Boscia G, Giannaccare G, Santoro M, Petrara G, Borriello C, et al. Topographical quantification of hyper-reflective foci may predict the development of macular atrophy in patients with neovascular age-related macular degeneration. Investig Ophthalmol Vis Sci. 2024;65:45. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39739348\/","DOI":"10.1167\/iovs.65.14.45"},{"key":"4306_CR12","doi-asserted-by":"crossref","unstructured":"Borrelli E, Boscia G, Gelormini F, Ricardi F, Ghilardi A, Marolo P, et al. Macular thickness and visual acuity are characterised by a quadratic nonlinear relation in previously treated neovascular AMD eyes. Eur J Ophthalmol. 2025;35:650\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39094557\/","DOI":"10.1177\/11206721241265998"},{"key":"4306_CR13","doi-asserted-by":"crossref","unstructured":"Boscia G, Pozharitskiy N, Grassi MO, Borrelli E, D\u2019Addario M, Alessio G, et al. Choroidal remodeling following different anti-VEGF therapies in neovascular AMD. Sci Rep. 1941;14;20\u20138.","DOI":"10.1038\/s41598-024-52315-w"},{"key":"4306_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of Atrophy Report 3. Ophthalmology. 2018;125:537\u201348.","journal-title":"Ophthalmology"},{"key":"4306_CR15","doi-asserted-by":"crossref","unstructured":"Fleckenstein M, Mitchell P, Freund KB, Sadda SV, Holz FG, Brittain C, et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2018;125:369\u201390. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29110945\/","DOI":"10.1016\/j.ophtha.2017.08.038"},{"key":"4306_CR16","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","volume":"122","author":"AS Willoughby","year":"2015","unstructured":"Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, et al. Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122:1846\u20131853.e5.","journal-title":"Ophthalmology"},{"key":"4306_CR17","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","volume":"121","author":"E Daniel","year":"2014","unstructured":"Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, et al. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:656\u201366.","journal-title":"Ophthalmology"},{"key":"4306_CR18","doi-asserted-by":"crossref","unstructured":"Borrelli E, Bandello F, Souied EH, Barresi C, Miere A, Querques L, et al. Neovascular age-related macular degeneration: advancement in retinal imaging builds a bridge between histopathology and clinical findings. Graefes Arch Clin Exp Ophthalmol. 2022;260:2087\u201393. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35122134\/","DOI":"10.1007\/s00417-022-05577-x"},{"key":"4306_CR19","doi-asserted-by":"crossref","unstructured":"Nanji K, Grad J, Hatamnejad A, McKechnie T, Phillips M, Cheung CMG, et al. Baseline OCT biomarkers predicting visual outcomes in neovascular age-related macular degeneration: a meta-analysis. Ophthalmology. 2025; Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40570933\/","DOI":"10.1016\/j.ophtha.2025.06.018"},{"key":"4306_CR20","doi-asserted-by":"crossref","unstructured":"Toto L, Evangelista F, Viggiano P, Erroi E, D\u2019Onofrio G, Libertini D, et al. Changes in ocular blood flow after ranibizumab intravitreal injection for diabetic macular edema measured using laser speckle flowgraphy. Biomed Res Int. 2020;2020:9496242.","DOI":"10.1155\/2020\/6219089"},{"key":"4306_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3928\/23258160-20191031-11","volume":"50","author":"E Borrelli","year":"2019","unstructured":"Borrelli E, Viggiano P, Evangelista F, Toto L, Mastropasqua R. Eyelashes artifact in ultra-widefield optical coherence tomography angiography. Ophthalmic Surg Lasers Imaging Retina. 2019;50:740\u20133.","journal-title":"Ophthalmic Surg Lasers Imaging Retina."},{"key":"4306_CR22","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1167\/iovs.11-8755","volume":"53","author":"Y Huang","year":"2012","unstructured":"Huang Y, Gangaputra S, Lee KE, Narkar AR, Klein R, Klein BEK, et al. Signal quality assessment of retinal optical coherence tomography images. Investig Ophthalmol Vis Sci. 2012;53:2133\u201341.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4306_CR23","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1097\/IAE.0000000000004157","volume":"44","author":"P Viggiano","year":"2024","unstructured":"Viggiano P, Bisceglia G, Bacherini D, Chhablani J, Grassi MO, Boscia G, et al. Long-term visual outcomes and optical coherence tomography biomarkers in eyes with macular edema secondary to retinal vein occlusion following anti-vascular endothelial growth factor therapy. Retina. 2024;44:1572\u20139.","journal-title":"Retina"},{"key":"4306_CR24","doi-asserted-by":"crossref","unstructured":"Viggiano P, Vujosevic S, Palumbo F, Grassi MO, Boscia G, Borrelli E, et al. Optical coherence tomography biomarkers indicating visual enhancement in diabetic macular edema resolved through anti-VEGF therapy: OCT biomarkers in resolved DME. Photodiagnosis Photodyn Ther. 2024;46. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38460657\/","DOI":"10.1016\/j.pdpdt.2024.104042"},{"key":"4306_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/tvst.8.6.5","volume":"8","author":"E Borrelli","year":"2019","unstructured":"Borrelli E, Costanzo E, Parravano M, Viggiano P, Varano M, Giorno P, et al. Impact of bleaching on photoreceptors in different intermediate AMD phenotypes. Transl Vis Sci Technol. 2019;8:5\u20135.","journal-title":"Transl Vis Sci Technol"},{"key":"4306_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajo.2023.03.033","volume":"252","author":"F Romano","year":"2023","unstructured":"Romano F, Cozzi E, Airaldi M, Nassisi M, Viola F, Aretti A, et al. Ten-Year incidence of fibrosis and risk factors for its development in neovascular age-related macular degeneration. Am J Ophthalmol. 2023;252:170\u201381.","journal-title":"Am J Ophthalmol"},{"key":"4306_CR27","doi-asserted-by":"crossref","unstructured":"Berni A, Coletto A, Li J, Shen M, Bandello F, Reibaldi M, et al. Macular atrophy in neovascular age-related macular degeneration: a systematic review and meta-analysis. Ophthalmol Retina. 2025;9:625\u201344. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39842718\/","DOI":"10.1016\/j.oret.2025.01.011"},{"key":"4306_CR28","doi-asserted-by":"crossref","unstructured":"Olivieri C, Tibaldi T, Berni A, Eandi CM, Neri G, Fai A, et al. Quantifying macular atrophy in neovascular AMD using en face structural OCT imaging. Eye. 2025; Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40634735\/","DOI":"10.1038\/s41433-025-03909-9"},{"key":"4306_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2017.06.005","volume":"181","author":"E Borrelli","year":"2017","unstructured":"Borrelli E, Abdelfattah NS, Uji A, Nittala MG, Boyer DS, Sadda SVR. Postreceptor neuronal loss in intermediate age-related macular degeneration. Am J Ophthalmol. 2017;181:1\u201311.","journal-title":"Am J Ophthalmol"},{"key":"4306_CR30","doi-asserted-by":"crossref","unstructured":"Yap DWT, Tan BKJ, Chong KTY, Wong TY, Cheung CMG. Persistence of retinal fluid after anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review and meta-analysis. Ophthalmol Retina. 2025;9:603\u201317. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39842717\/","DOI":"10.1016\/j.oret.2025.01.010"},{"key":"4306_CR31","doi-asserted-by":"crossref","unstructured":"Berni A, Foti C, Bandello F, Boscia F, Breazzano MP, Cicinelli MV, et al. Predictors of macular atrophy after serous pigment epithelial detachment collapse in type 3 macular neovascularization and age-related macular degeneration. Ophthalmol Retina. 2025; Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40441379\/","DOI":"10.1016\/j.oret.2025.05.028"},{"key":"4306_CR32","unstructured":"Costa I, Carvalho A, Andrade H, Pereira B, Camacho P. Neurodegeneration and choroidal vascular features on OCT in the progression to advanced age-related macular degeneration. Int J Ophthalmol. 2025;18:103\u201310. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39829629\/"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04306-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04306-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04306-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T15:20:19Z","timestamp":1775661619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04306-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4306"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04306-6","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Enrico Borrelli is a member of the Eye editorial board. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}